Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain
SCIENCE • 2 Dec 2021 • First Release • DOI: 10.1126/science.abl6251
Abstract
Many studies have examined the impact of SARS-CoV-2 variants on neutralizing antibody activity after they have become dominant strains. Here, we evaluate the consequences of further viral evolution. We demonstrate mechanisms through which the SARS-CoV-2 receptor binding domain (RBD) can tolerate large numbers of simultaneous antibody escape mutations and show that pseudotypes containing up to seven mutations, as opposed to the one to three found in previously studied variants of concern, are more resistant to neutralization by therapeutic antibodies and serum from vaccine recipients. We identify an antibody that binds the RBD core to neutralize pseudotypes for all tested variants but show that the RBD can acquire an N-linked glycan to escape neutralization. Our findings portend continued emergence of escape variants as SARS-CoV-2 adapts to humans.
For details, please visit https://www.science.org/doi/10.1126/science.abl6251
Magen is paying her effort to help the resistance of new virus and has devleoped a complete solution for virus nucleic acid extration, including DNA/RNA extraction kits, raw materials and automated extraction machines.
For details please visit: http://www.magen-tec.com/technicalsolutions/info.aspx?itemid=391&lcid=132
